| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Not applicable; Periplanetin is a natural product and not known to have a specific molecular target. It may function as an insect pheromone or defensive secretion component. Its role in biological systems is not well established.
|
|---|---|
| ln Vitro |
Periplanetin exhibits notable solubility in aqueous solutions facilitating its integration into biochemical assays. It is expected to be metabolized by beta-glucosidases, releasing benzoic acid and glucose. The compound may have antimicrobial or insecticidal activity, but no specific in vitro activity has been characterized in the search results.
|
| ln Vivo |
No specific in vivo activity has been reported. As a natural product isolated from cockroach secretions, it may play a role in insect defense mechanisms. No animal model studies have been published for this compound.
|
| Enzyme Assay |
Standard protocols for studying periplanetin involve its isolation and identification. For enzyme hydrolysis studies, periplanetin (1 mg/mL) is incubated with beta-glucosidase (10 U/mL) in 0.1 M sodium acetate buffer (pH 5.0) at 37degC for 1-4 hours. The reaction products (glucose and benzoic acid) are analyzed by HPLC or enzymatic assay. Binding to proteins is not assessed.
|
| Cell Assay |
Cell culture studies are not typically performed with this compound. For cytotoxicity screening, insect cell lines (e.g., Sf9) could be used. Cells are seeded in 96‑well plates at 1×10⁵ cells/well and treated with periplanetin (0.1-1000 microg/mL) for 48 hours. Cell viability is determined by MTT or trypan blue exclusion. No published protocols are available for this research reagent.
|
| Animal Protocol |
Periplanetin is not typically administered to animals. For insect behavior studies, the compound (1-100 microg) may be applied to filter paper or an insect's cuticle to observe its effect as a potential pheromone or repellent. No standard in vivo animal dosing protocols are available. The compound is isolated from natural sources and used as an analytical standard.
|
| ADME/Pharmacokinetics |
Periplanetin is a natural product, and no PK data is available. As a beta-glucose ester, it is likely hydrolyzed by beta-glucosidases in the gut, releasing benzoic acid and glucose. Benzoic acid is then metabolized via conjugation with glycine (hippuric acid) and excreted in urine. The glucose is absorbed and utilized metabolically.
|
| Toxicity/Toxicokinetics |
No toxicity data is available for periplanetin. Benzoic acid (a hydrolysis product) has low toxicity; the oral LD50 in rats is approximately 1700 mg/kg. Glucose is harmless. Therefore, periplanetin is unlikely to be acutely toxic, but this has not been formally tested.
|
| References | |
| Additional Infomation |
Benzoyl-β-D-glucoside is a β-D-glucoside whose function is related to benzoic acid. It has been reported to exist in lauryl cherry (Prunus laurocerasus), black cherry (Prunus serotina), and other organisms with relevant data.
Periplanetin is also known as benzoyl beta-D-glucoside, benzoyl beta-D-glucopyranoside, and glucosyl benzoate. It is a white to off-white solid powder. It is used as a natural product reference standard and for research into insect biochemistry. It is not approved for clinical use. Molecular formula: C13H16O7; molecular weight: 284.26. |
| Molecular Formula |
C13H16O7
|
|---|---|
| Molecular Weight |
284.2619
|
| Exact Mass |
284.09
|
| CAS # |
21056-52-0
|
| PubChem CID |
12314096
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5g/cm3
|
| Boiling Point |
507.1ºC at 760 mmHg
|
| Flash Point |
194.1ºC
|
| Vapour Pressure |
4.19E-11mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
329
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC=C(C=C1)C(=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
|
| InChi Key |
LVFCLUMIBMHAFL-HMUNZLOLSA-N
|
| InChi Code |
InChI=1S/C13H16O7/c14-6-8-9(15)10(16)11(17)13(19-8)20-12(18)7-4-2-1-3-5-7/h1-5,8-11,13-17H,6H2/t8-,9-,10+,11-,13+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | |
| 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | |
| 10 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
